PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29199322-0	2016	Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer"s Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair.	lanabecestat	58-65	beta-secretase 2	Homo sapiens	141-146	
29199322-1	2016	BACKGROUND: AZD3293 (also known as LY3314814) is a novel, potent, non-selective BACE1/BACE2 inhibitor currently in Phase 3 clinical development for the treatment of Alzheimer"s disease.	lanabecestat	12-19	beta-secretase 2	Homo sapiens	86-91	
29199322-1	2016	BACKGROUND: AZD3293 (also known as LY3314814) is a novel, potent, non-selective BACE1/BACE2 inhibitor currently in Phase 3 clinical development for the treatment of Alzheimer"s disease.	lanabecestat	35-44	beta-secretase 2	Homo sapiens	86-91	
29199322-22	2016	CONCLUSIONS: AZD3293, a novel, potent, non-selective BACE1/BACE2 inhibitor is in development as a potentially disease-modifying treatment for Alzheimer"s disease.	lanabecestat	13-20	beta-secretase 2	Homo sapiens	59-64